BACKGROUND: BRAF inhibitors are effective against selected BRAF V600 -mutated tumors. Preclinical data suggest that BRAF inhibition in conjunction with chemotherapy has increased therapeutic activity. METHODS: Patients with advanced cancers and BRAF mutations were enrolled into a dose-escalation study (3+3 design) to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs). RESULTS: Nineteen patients with advanced cancers and BRAF mutations were enrolled and received vemurafenib (480-720 mg orally twice a day), carboplatin (area under the curve [AUC] 5-6 intravenously every 3 weeks), and paclitaxel (100-135 mg/m 2 intravenously every 3 weeks). The MTD was not reached, and vemurafenib at 720 mg twice a day, carboplatin at AUC 5, and paclitaxel at 135 mg/m 2 were the last safe dose levels. DLTs included a persistent grade 2 creatinine elevation (n = 1), grade 3 transaminitis (n = 1), and grade 4 thrombocytopenia (n = 1). Non-dose-limiting toxicities that were grade 3 or higher and occurred in more than 2 patients included grade 3/4 neutropenia (n = 5), grade 3/4 thrombocytopenia (n = 5), grade 3 fatigue (n = 4), and grade 3 anemia (n = 3). Of the 19 patients, 5 (26%; all with melanoma) had a partial response (PR; n = 4) or complete response (CR; n = 1); these responses were mostly durable and lasted 3.1 to 54.1 months. Of the 13 patients previously treated with BRAF and/or mitogenactivated protein kinase kinase (MEK) inhibitors, 4 (31%) had a CR (n = 1) or PR (n = 3). Patients not treated with prior platinum therapy had a higher response rate than those who did (45% vs 0%; P = .045). CONCLUSIONS: The combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and BRAF V600 mutations, regardless of prior treatment with BRAF and/or MEK inhibitors.
INTRODUCTION
Mutations in the BRAF oncogene, which encodes a serine/threonine kinase leading to activation of the mitogenactivated protein kinase pathway, have been reported in 7% to 9% of advanced cancers, with the highest incidence in melanoma (50%), which is followed by papillary thyroid cancer (45%), low-grade serous ovarian cancer (35%), colorectal cancer (11%-12%), and non-small cell lung cancer (NSCLC; 3%-5%). [1] [2] [3] [4] [5] [6] [7] The most common activating somatic point mutation is BRAF V600E , a substitution of valine to glutamic acid in the glycine-rich loop. 4 
BRAF inhibitors
Cancer February 1, 2019 such as vemurafenib and dabrafenib have demonstrated preclinical and clinical activity against several advanced cancers with BRAF V600 mutations and have been approved by the US Food and Drug Administration for the treatment of advanced melanoma, Erdheim-Chester disease, and NSCLC (in combination with trametinib) with BRAF V600E or other BRAF V600 mutations. [8] [9] [10] [11] Carboplatin and paclitaxel have demonstrated antitumor activity in chemotherapy-naive patients with metastatic melanoma, with response rates of 11% to 18% and a median progression-free survival (PFS) duration of 4.2 months. 12, 13 Carboplatin and paclitaxel are the standard of care for other malignancies known to have BRAF mutations, including advanced ovarian cancer and NSCLC. 14, 15 Preclinical studies demonstrated that BRAF inhibition plus chemotherapy could inhibit cell growth in in vitro and in vivo xenograft models. This led to the development of combined sorafenib, carboplatin, and paclitaxel treatment for metastatic melanoma, which, despite encouraging early data, failed in randomized trials. 13, [16] [17] [18] This failure could have been due to sorafenib's weak inhibitory activity on the BRAF kinase and its lack of molecular selection for tumors harboring BRAF mutations. We hypothesized that unlike sorafenib, vemurafenib is a potent selective inhibitor of the mutated BRAF kinase that can have synergistic activity with carboplatin and paclitaxel. Therefore, we designed a phase 1 clinical study to determine the maximum tolerated dose (MTD), safety, and early signals of clinical activity of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated advanced cancers.
MATERIALS AND METHODS

Study Design and Objectives
This was an open-label, nonrandomized, 3+3 doseescalation phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated advanced cancers (NCT01636622). The primary endpoints were to establish the regimen's MTD or recommended phase 2 dose and to evaluate its dose-limiting toxicities (DLTs) and safety. The secondary endpoints were to evaluate early signals of efficacy such as the response rate. The study was performed at The University of Texas MD Anderson Cancer Center. The study protocol was approved by MD Anderson's institutional review board. All patients provided written informed consent before starting study-related procedures.
Eligible patients had a histologically or cytologically confirmed diagnosis of a refractory advanced solid tumor harboring a BRAF mutation detected in a Clinical Laboratory Improvement Amendments-approved laboratory, had measurable disease according to the Response Evaluation Criteria in Solid Tumors (version 1.1), 19 and had been off prior systemic cancer therapies for at least 3 weeks (in the case of chemotherapy) or 5 half-lives (in the case of biologic treatments except for BRAF inhibitors, which required no washout). Other inclusion criteria included a QTc interval < 500 milliseconds; an Eastern Cooperative Oncology Group performance status of 0 to 2; and adequate bone marrow, liver, and renal function (total bilirubin level ≤ 2 × upper limit of normal [ULN]; aspartate aminotransferase and alanine aminotransferase levels ≤ 2.5 × ULN or, if liver metastasis was present, ≤ 5 × ULN; serum creatinine level ≤ 2 × ULN; platelet count > 75,000/mL; absolute neutrophil count > 1000/mL; and hemoglobin level >8.0 g/dL).
Treatment dose levels are given in Table 1 . Vemurafenib (480-720 mg) was given orally twice daily for 21 days and was started the evening of the day after the administration of paclitaxel (100-135 mg/m 2 ) and carboplatin (area under the curve [AUC] 5-6). Paclitaxel and carboplatin were given intravenously on day 1 of the 21-day cycle until disease progression or unacceptable toxicity. Safety was assessed with the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 4), and DLTs were evaluated during the first 21 days of therapy.
DLTs were treatment-related grade 3 or higher hemolytic anemia; grade 4 thrombocytopenia; grade 3 or higher febrile neutropenia; grade 4 neutropenia lasting (B) For a patient with melanoma and a BRAF V600E mutation who was previously treated with an MEK inhibitor and attained a complete response, baseline and week 6 computed tomography scans demonstrate the complete resolution of the abdominal implant. (C) For a patient with melanoma and a BRAF V600K mutation who was previously treated with a BRAF inhibitor and attained a partial response (-51%), baseline and week 6 computed tomography scans demonstrate an improvement in bilateral pleural effusion and mediastinal lymphadenopathy. (D) For a patient with melanoma and a BRAF V600E mutation who attained a partial response (-31%), baseline and week 6 computed tomography scans demonstrate an improvement in the left breast mass. There were 2 remaining patients who attained partial responses (-30% and -50%, respectively): a patient with melanoma and a BRAF V600E mutation previously treated with a BRAF inhibitor is depicted with pertinent images and plasma cell-free DNA in Figure 3A , and another patient with melanoma and a BRAF V600E mutation previously treated with a BRAF inhibitor is not depicted because of computed tomography without intravenous contrast. ERK indicates extracellular signal-regulated kinase; MEK, mitogen-activated protein kinase kinase; SD, stable disease. , and NRAS Q61H 183A>C ) with the QX200 ddPCR system (Bio-Rad) according to the manufacturer's standard protocol. The lower limit of detection was an approximately 0.2% mutant allele frequency for the multiplexed screening assay and a <0.1% mutant allele frequency per single well for the mutation-specific assays.
Statistical Analysis
The PFS duration was defined as the time from the initiation of systemic therapy to the date of disease progression or death from any cause. The overall survival (OS) duration was defined as the time from the initiation of systemic therapy to the date of death or last follow-up. The Kaplan-Meier method was used to estimate PFS and OS, and a log-rank test was used to compare PFS or OS among patient subgroups. All tests were 2-sided, and P values < .05 were considered statistically significant. Statistical analyses were performed with the SPSS 21 software program (SPSS, Chicago, Illinois).
RESULTS
Patient Characteristics
Of 23 patients screened from October 2012 to April 2014, 19 met the eligibility criteria and were enrolled in the study (Supporting Fig. 1 ). The clinical characteristics of these 19 patients are described in Table 2 . The median age was 53 years (range, 33-75 years), and most patients were men (n = 11 [58%]) and white (n = 15 [79%]). Melanoma was the most common tumor type (n = 13 [68%]) and was followed by papillary thyroid cancer (n = 1 [5%]), anal squamous cell carcinoma (n = 1 [5%]), cholangiocarcinoma (n = 1 [5%]), spindle cell sarcoma (n = 1 [5%]), pancreatic carcinoma (n = 1 [5%]), and adenocarcinoma of an unknown primary (n = 1 [5%]). Patients had received a median of 3 lines of prior therapies (range, 1-7 therapies). In addition, 13 patients (68%) received 1 or more lines of prior treatment with BRAF and/or mitogen-activated protein kinase kinase (MEK) inhibitors (1 line, 9 patients; 2 lines, 2 patients; and >2 lines, 2 patients).
Toxicity
Of the 19 patients enrolled at 4 dose levels, 18 (95%) were evaluable for toxicity (1 patient withdrew consent before completing cycle 1). DLTs included a grade 2 creatinine elevation for longer than 7 consecutive days in 1 patient at dose level 1 and grade 3 transaminitis with grade 4 thrombocytopenia in 1 patient at dose level 3 Cancer February 1, 2019
( Table 1 ). The MTD was not reached by the end of the study, and dose level 3 (vemurafenib at 720 mg orally twice per day, carboplatin at AUC 5 intravenously every 3 weeks, and paclitaxel at 135 mg/m 2 intravenously every 3 weeks) was the last dose level proven to be safe. Only 1 patient was treated at dose level 4 before the institutional review board halted the study because of slow enrollment. DLTs aside, the most frequent treatment-related grade 3 Table 3 ). Other grade 3 or 4 treatment-related toxicities included anorexia, an altered mental status, bacteremia, dehydration, handfoot syndrome, hypokalemia, hypophosphatemia, mucositis, nausea, vomiting, transaminitis, and weight loss. One patient had a fatal (grade 5) intracranial hemorrhage that was possibly related to the study drug. Seven patients (37%) required dose reductions of carboplatin and/or paclitaxel (n = 5), vemurafenib (n = 1), or carboplatin and vemurafenib (n = 1) because of hematological toxicity, fatigue, hand-foot syndrome, or peripheral neuropathy. In addition, 5 patients (26%) received granulocyte colony-stimulating factor to treat or prevent neutropenia, 6 (32%) required blood transfusions, and 4 (21%) received platelet transfusions. Treatment-related squamous cell carcinoma of the skin and actinic keratosis were each reported in 1 patient (5%). No patients had grade 3 or higher or clinically significant QTc prolongation.
Efficacy
Of the 19 patients enrolled in the study, 16 (84%) were evaluable for a response, and 5 (26% of all patients and 31% of the evaluable patients) had a complete response (CR) or partial response (PR). Three patients did not have restaging computed tomography or magnetic resonance imaging because they discontinued treatment on account of clinical progression, consent withdrawal, or a treatment-related intracranial hemorrhage resulting in death. One patient with melanoma and a BRAF V600E mutation who had received 3 lines of prior therapies for metastatic disease, including 8 months of therapy with the MEK inhibitor trametinib, had a CR (Table 4 ). This patient was taken off the study after 26 cycles of treatment because of a continuing CR and remained progression-free at 54.1 months (Fig. 1A,B and Table 4 ). Four patients with melanoma, 3 of whom received prior BRAF inhibitors, attained PRs (-51%, -50%, -31%, and -30%; Fig. 1A ,C,D and Table 4 ). In addition, 8 patients had stable disease (-24% to 0%); in 4 of these patients, it lasted longer than 4 months (4.8, 4.9, 8.6, and >25.1 months; Fig. 1A) .
The CR/PR rates of the 6 patients not previously treated with BRAF or MEK inhibitors and the 13 patients previously treated with BRAF and/or MEK inhibitors did not differ significantly (1 of 6 [17%] vs 4 of 13 [31%]; P = 1.00), nor did those of the 16 patients not previously treated with taxanes and the 3 patients previously treated with taxanes (4 of 16 [25%] vs 1 of 3 [33%]; P = 1.00). However, the CR/PR rate of 11 patients not previously treated with platinum agents was significantly higher than that of 8 patients previously treated with platinum agents (5 of 11 [45%] vs 0 of 8 [0%]; P = .045).
The median PFS duration for all 19 patients was 3.7 months (95% confidence interval [CI], 2.5-4.9 months). The median PFS durations for 6 patients not previously treated with BRAF or MEK inhibitors and 13 patients previously treated with BRAF and/or MEK inhibitors did not differ significantly (1.9 months [95% CI, 0.3-3.5 months] vs 3.7 months [95% CI, 0.8-6.6 months]; P = .41; Fig. 2A ). In addition, the median PFS durations for 16 patients not previously treated with taxanes and 3 patients previously treated with taxanes did not differ significantly (3.7 months [95% CI, 1.1-6.3 months] vs 3.1 months [95% CI, 0.0-6.9 months]; P = .25; Fig. 2B ). The median progression-free survival duration of 13 patients previously treated with BRAF and/or MEK inhibitors (3.7 months; 95% CI, 0.8-6.6 months; red) and that of 6 patients not previously treated with BRAF or MEK inhibitors (1.9 months; 95% CI, 0.3-3.5 months; blue) did not differ significantly (P = .41). (B) The median progression-free survival duration of 3 patients previously treated with taxanes (3.1 months; 95% CI, 0.0-6.9 months; red) and that of 16 patients not previously treated with taxanes (3.7 months; 95% CI, 1.1-6.3 months; blue) did not differ significantly (P = .25). (C) The median progression-free survival duration of 8 patients previously treated with platinum therapy (2.0 months; 95% CI, 0.8-3.2 months; red) was significantly shorter than that of 11 patients not previously treated with platinum therapy (8.6 months; 95% CI, 3.0-14.2 months; blue; P = .005). CI indicates confidence interval; MEK, mitogen-activated protein kinase kinase. Cancer February 1, 2019 months [95% CI, 3.7-14.5 months]; P = .50; Supporting Fig. 2A ). In addition, there was a trend toward a longer median OS duration for 16 patients not previously treated with taxanes in comparison with 3 patients previously treated with taxanes (9.1 months [95% CI, 0.1-18.1 months] vs 3.5 months [95% CI, 0.5-6.5 months]; P = .06; Supporting Fig. 2B ). The median OS duration for 11 patients not previously treated with platinum agents was significantly longer than that for 8 patients previously treated with platinum agents (13. 
PLASMA CFDNA ANALYSIS
Of the 19 patients, 11 (58%; all with BRAF V600 mutations) had blood collection before therapy for the molecular analysis of plasma-derived cfDNA. Of these 11 patients, 8 were receiving a BRAF inhibitor and 1 was receiving an MEK inhibitor immediately before study enrollment. Of these 11 patients, 8 had additional serial blood collection of 1 or more samples during therapy. BRAF V600 mutations in plasma cfDNA were detected in blood samples collected before therapy in 5 patients (45%) and in blood samples collected at any time in 7 patients (64%). The median numbers of BRAF V600 mutant Figure 3 . Dynamic tracking of the number of BRAF V600E -mutant copies in cell-free DNA (red) isolated from serially collected plasma samples and corresponding images of selected targeted lesions in (A) a patient with melanoma and a PR, (B) a patient with melanoma and stable disease, (C) a patient with melanoma and stable disease, (D) a patient with papillary thyroid cancer and stable disease, (E) a patient with melanoma and stable disease, and (F) a patient with intrahepatic cholangiocarcinoma and unconfirmed stable disease. PR indicates partial response; SD, stable disease.
Cancer February 1, 2019 copies in plasma cfDNA collected before therapy (24.5; range, 0-1672), during therapy (16.5; range, 0-608), and at disease progression (275.5; range, 13-710) differed significantly (P = .03; Supporting Fig. 3) . Of the 8 patients who had serial blood collection, 6 had detectable BRAF V600E -mutant cfDNA. Dynamic changes in BRAF V600E -mutant cfDNA corresponded with the clinical disease course and often indicated upcoming disease progression (Fig. 3) . We also performed testing for KRAS mutations in exon 2 and for NRAS mutations in exons 2 and 3 because these mutations could be implicated in adaptive resistance to BRAF inhibitors; however, none of the plasma cfDNA samples demonstrated any of these mutations. 20 
DISCUSSION
The combination of vemurafenib, carboplatin, and paclitaxel demonstrated an acceptable safety profile and promising signals of anticancer activity in patients with advanced cancers and BRAF V600 mutations. Most of the observed grade 3 or higher toxicities were hematological (eg, thrombocytopenia requiring platelet transfusions in 21% of the patients) and were deemed to be related to the chemotherapy portion (ie, carboplatin and paclitaxel) of the combination. Although the study did not meet its primary endpoint of determining MTD, it demonstrated that vemurafenib, carboplatin, and paclitaxel have noteworthy clinical activity. The institutional review board requested that enrollment be stopped because of the slower than anticipated enrollment. The accrual had been affected during the second half of the study by the boom of immunotherapy clinical trials, which resulted in the opening of a variety of competing protocols. The study enrolled patients for 4 of the 6 planned dose levels, and because only 1 patient was treated at dose level 4, dose level 3 (vemurafenib at 720 mg, carboplatin at AUC 6, and paclitaxel at 135 mg/m 2 ) was established as the last safe dose level. Nevertheless, despite these limitations, our trial suggests that the combination of vemurafenib, carboplatin, and paclitaxel has noteworthy clinical activity across all dose levels, with 3 of 5 PRs occurring at dose level 1.
The PR/CR rates in the current study were 26% (5 of 19) for all patients and 31% (5 of 16) for patients evaluable for a response, and responses were independent of prior BRAF and/or MEK inhibitor use; however, it needs to be noted that 3 of the 6 patients in our study who were naive to BRAF and MEK inhibitors had BRAF non-V600 mutations. The enrollment of patients with BRAF non-V600 mutations was then discouraged as we took into account available preclinical data and the lack of activity observed in our own patient population. 21 In patients previously treated with BRAF and/or MEK inhibitors, the PR/CR rate was 31% (4 of 13), and the responses, lasting 3.1, 14.0, >15.4, and >54.1 months, were mostly durable. This compares favorably with previously published response rates of 11% to 18% in chemotherapy-naive patients with metastatic melanoma treated with carboplatin and paclitaxel and with some published results for targeted treatment strategies for patients with BRAF-mutated melanoma previously treated with BRAF inhibitors. 12, 13, 22 For instance, the first-in-class extracellular signal-regulated kinase inhibitor ulixertinib demonstrated a PR/CR rate of 16% (3 of 19) in patients with advanced BRAF V600 -mutated melanoma previously treated with BRAF and/or MEK inhibitors. 23 However, the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with advanced BRAF V600 -mutated melanoma previously treated until progression with a BRAF inhibitor without or with an MEK inhibitor followed by a treatment break demonstrated CR/PR rates of 32% to 37%. 24, 25 This relatively high CR/PR rate can be explained by a suppression of resistance clones after discontinuation of a BRAF inhibitor. In our study, it remains unclear whether encouraging activity observed in BRAF V600 -mutated melanoma previously treated with BRAF and/or MEK inhibitors reflects the ability of the studied combination to combat resistance or regained sensitivity. In our study, an exploratory analysis demonstrated no significant difference in the PR/CR rates (P = 1.00) or median PFS durations (P = .41) of patients with or without prior treatment with BRAF and/or MEK inhibitors. However, patients not previously treated with platinum-based chemotherapy had a significantly higher PR/CR rate (P = .045) and longer median PFS duration (P = .005) than patients with a history of prior platinum-based therapy. Therefore, it is plausible that platinum-based chemotherapy could play a role in overcoming resistance induced by BRAF inhibitors, MEK inhibitors, or other therapies.
We did not identify any BRAF V600 mutations in plasma cfDNA samples collected before therapy in 6 of 11 patients, and this resulted in a sensitivity of only 45% in comparison with the archival tumor tissue testing. This is noticeably less than the sensitivity of 73% to 81% reported by us and others from other studies using various digital polymerase chain reactions. [26] [27] [28] This can be explained by the fact that, of the 11 patients whose Cancer February 1, 2019 plasma cfDNA was collected, 9 had been receiving BRAF or MEK inhibitors before enrolling in the study, and this could have led to the elimination of BRAF V600 -mutated cfDNA from plasma. In agreement with previously published literature, the number of BRAF V600 -mutant cfDNA copies differed among samples collected before therapy, during therapy, and at disease progression (P = .03). 29 Dynamic changes in BRAF V600E cfDNA in plasma overall corresponded with the clinical course; however, the emergence of RAS mutations indicating therapeutic resistance was not detected. Our study had several potential limitations. First, even though the clinical activity was noteworthy, the study did not meet its primary endpoint of identifying the MTD. Second, the number of patients enrolled was relatively small, and all PRs and CRs were observed in patients with BRAF V600 -mutated melanoma; therefore, whether the drug combination has potential for further development in other tumor types remains unclear. Third, the study was designed in 2012, shortly before the results of the first phase 1 trial of the anti-programmed cell death protein 1 (anti-PD1) antibody nivolumab were published. 30 In our study, only 5 patients with melanoma received prior checkpoint inhibitors, and only 1 had received an anti-PD1 antibody; thus, how the combination tested in the current study should be positioned in current therapeutic strategies for advanced melanoma with BRAF V600 mutations is not clear.
Despite these limitations, our study has demonstrated one of the most promising signals of anticancer efficacy in advanced melanoma with BRAF V600 mutations previously treated with BRAF and/or MEK inhibitors. Further investigation of the combination of vemurafenib, carboplatin, and paclitaxel in this setting is warranted.
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